Youjia Hu, PhD
Associate Research Scientist (Endocrinology)
Research & Publications
Biography
Coauthors
Selected Publications
- Tlr9 deficiency in B cells leads to obesity by promoting inflammation and gut dysbiosisWang P, Yang X, Zhang L, Sha S, Huang J, Peng J, Gu J, Pearson J, Hu Y, Zhao H, Wong F, Wang Q, Wen L. Tlr9 deficiency in B cells leads to obesity by promoting inflammation and gut dysbiosis. Nature Communications 2024, 15: 4232. PMID: 38762479, PMCID: PMC11102548, DOI: 10.1038/s41467-024-48611-8.
- TLR5-deficiency controls dendritic cell subset development in an autoimmune diabetes-susceptible modelPearson J, Hu Y, Peng J, Wong F, Wen L. TLR5-deficiency controls dendritic cell subset development in an autoimmune diabetes-susceptible model. Frontiers In Immunology 2024, 15: 1333967. PMID: 38482010, PMCID: PMC10935730, DOI: 10.3389/fimmu.2024.1333967.
- Identification of a New Integration Site and Study on Site-Specific Integration in CHO-K1 CellsLiu H, Zhang W, Xie L, Hu Y. Identification of a New Integration Site and Study on Site-Specific Integration in CHO-K1 Cells. Pharmaceuticals 2023, 17: 8. PMID: 38275994, PMCID: PMC10819697, DOI: 10.3390/ph17010008.
- Generation and Characterization of SORT1-Targeted Antibody–Drug Conjugate for the Treatment of SORT1-Positive Breast TumorZhuang W, Zhang W, Xie L, Wang L, Li Y, Wang Z, Zhang A, Qiu H, Feng J, Zhang B, Hu Y. Generation and Characterization of SORT1-Targeted Antibody–Drug Conjugate for the Treatment of SORT1-Positive Breast Tumor. International Journal Of Molecular Sciences 2023, 24: 17631. PMID: 38139459, PMCID: PMC10743877, DOI: 10.3390/ijms242417631.
- Squalene Biosynthesis in Engineered Escherichia ColiZhang W, Li Y, Xie L, Hu Y. Squalene Biosynthesis in Engineered Escherichia Coli. Pharmaceutical Fronts 2023, 05: e321-e329. DOI: 10.1055/s-0043-1776291.
- Generation of a Novel SORT1×HER2 Bispecific Antibody–Drug Conjugate Targeting HER2-Low-Expression TumorZhuang W, Zhang W, Wang L, Xie L, Feng J, Zhang B, Hu Y. Generation of a Novel SORT1×HER2 Bispecific Antibody–Drug Conjugate Targeting HER2-Low-Expression Tumor. International Journal Of Molecular Sciences 2023, 24: 16056. PMID: 38003245, PMCID: PMC10671096, DOI: 10.3390/ijms242216056.
- NLRP6 deficiency expands a novel CD103+ B cell population that confers immune tolerance in NOD micePearson J, Peng J, Huang J, Yu X, Tai N, Hu Y, Sha S, Flavell R, Zhao H, Wong F, Wen L. NLRP6 deficiency expands a novel CD103+ B cell population that confers immune tolerance in NOD mice. Frontiers In Immunology 2023, 14: 1147925. PMID: 36911699, PMCID: PMC9995752, DOI: 10.3389/fimmu.2023.1147925.